AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03920007
Drug: Trimethoprim/polymyxin B
RxNorm normalized name: Polymyxin B Sulfate/Trimethoprim Sulfate 10000 U/1 ML-1 MG/1 ML Ophthalmic Solution [TRIMETHOPRIM/POLYMYXIN B SULF]
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution Route of administration: Topical
Trial: NCT03724149
Drug: Zepatier
RxNorm normalized name: Zepatier
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
Trial: NCT00779792
Drug: glycerol
RxNorm normalized name: Glycerol
DrugBank: Glycerin (DB09462)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg glycerol ointment (20%) twice daily for 10 consecutive days
Trial: NCT00779792
Drug: vehicle ointment (paraffin oil/soft white paraffin)
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg vehicle ointment twice daily for 10 consecutive days
Trial: NCT03724149
Drug: Epclusa
RxNorm normalized name: Epclusa
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epclusa (sofosbuvir 400mg and velpatasvir 100mg once daily) is taken by mouth for 12 weeks. Study subjects with treatment failure will be provided an alternative DAA + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
Trial: NCT00163449
Drug: Ciclesonide
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efficacy and Safety of Ciclesonide
Trial: NCT02051309
Drug: Guanfacine
RxNorm normalized name: Guanfacine
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6mg/day ER with 3-week lead-in period. Maintained at steady state throughout 8 week treatment phase. After treatment phase, given taper supply of medication. Follow up at 1 month, 2 months and 6 months.
Trial: NCT01284439
Drug: hydroxypropylmethylcellulose
RxNorm normalized name: hydroxypropylmethylcellulose
DrugBank: Hypromellose (DB11075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TearA: QID to every 2 hous , 1-2 drops per each time , duration 1 month
Trial: NCT01284439
Drug: sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: QID to every 2 hous, 1-2 drops per each time, duration 1 month
Trial: NCT01718938
Drug: velusetrag dose 1
RxNorm normalized name: Velusetrag
DrugBank: Velusetrag (DB12702)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01718938
Drug: velusetrag dose 2
RxNorm normalized name: Velusetrag
DrugBank: Velusetrag (DB12702)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01718938
Drug: velusetrag dose 3
RxNorm normalized name: Velusetrag
DrugBank: Velusetrag (DB12702)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00056160
Drug: CC-5013
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the CC-5013/Dex treatment group took 25 mg of lenalidomide orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle.
Trial: NCT00056160
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects in the CC-5013/Dex and Placebo/Dex treatment groups took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. Beginning with Cycle 5, the dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 for the remaining cycles.
Trial: NCT00411866
Drug: Ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole will be available as 200mg tablets.
Trial: NCT02984111
Drug: erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00927602
Drug: fondaparinux
RxNorm normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once daily sc injection, 1,5 mg, max 14 days
Trial: NCT04258163
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800-1200 mg/m 2 IV days 1, 8, and 15, cycled every 28 days
Trial: NCT04258163
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500mg IH Days 0, 14, 28, then every 28 days
Trial: NCT04258163
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg PO qd
Trial: NCT04258163
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5mg PO qd
Trial: NCT00152282
Drug: Asoprisnil/Premarin
DrugBank: Asoprisnil (DB06680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asoprisnil 5mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
Trial: NCT01621022
Drug: bupropion + nicotine gum
RxNorm normalized name: nicotine Chewing Gum
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg bupropion twice daily plus 4 mg nicotine gum as needed (up to 12 pcs/day)
Trial: NCT01621022
Drug: Placebo bupropion-Placebo gum
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo bupropion twice daily + placebo nicotine gum as needed (up to 12 pcs/day)
Trial: NCT02515422
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous infiltration of ketamine
Trial: NCT02515422
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous infiltration of bupivacaine
Trial: NCT02515422
Drug: Placebo (0.9% saline solution)
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01075581
Drug: Epinephrin (Intranasal injection)
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A total of 8 mL of epinephrine 1:100,000 will be injected in the lateral nasal wall, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
Trial: NCT01075581
Drug: Epinephrin (Topical administration)
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An intranasal injection of saline solution, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
Trial: NCT00583258
Drug: Placebo Alfuzosin
DrugBank: Alfuzosin (DB00346)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg PO once a day
Trial: NCT03654196
Drug: Umkamin(Active Comparator)
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total 7 days of treatment and The daily dose is as follows \[Morning: Placebo of HL301 1Tab + Umkamin 1Tab\] \[Noon: Umkamin 1Tab\] \[Evening: Placebo of HL301 1Tab + Umkamin 1Tab\]
Trial: NCT01195298
Drug: Capecitabine and Bevacizumab
RxNorm normalized name: Capecitabine
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drugs will be administered in 3-week cycles as follows:~* Bevacizumab 15mg/kg via i.v. infusion on day 1~* Capecitabine 1000 mg/m2 tablets twice-daily, on days 1 through 14.
Trial: NCT00444145
Drug: Prevacid
RxNorm normalized name: Prevacid
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg bid for 3 months
Trial: NCT04814745
Drug: intrathecal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: morphine 150 mcg will be used by intrathecal administration
Trial: NCT04814745
Drug: Ropivacaine injection
RxNorm normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bilateral transversus abdominis plane block by using ropivacaine 80 mg
Trial: NCT00775177
Drug: Doxycycline monohydrate 100mg tablets
RxNorm normalized name: doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bioequivalence Doxycycline monohydrate 100mg tablets fasting condition
Trial: NCT00592098
Drug: Strontium chloride hexahydrate
RxNorm normalized name: Strontium Chloride Hexahydrate
DrugBank: Strontium chloride (DB13987)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cutaneous solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
Trial: NCT04047290
Drug: AK112
RxNorm normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK112 is a PD1/VEGF bispecific antibody.
Trial: NCT03155048
Drug: oral estrogen replacement therapy
RxNorm normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral estradiol group for endometrial preparation
Trial: NCT00002725
Drug: bryostatin 1
RxNorm normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01204554
Drug: Indocyanine green (ICG)
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: a water-soluble dye that binds to plasma proteins and remains in the intravascular space after intravenous injection.ICG has a normal plasma half life of 3-4 min. Dosage planned is 0 .5 mg/kg dose of ICG resolved in 5 % dextrose 2 mg /ml.
Trial: NCT03830125
Drug: BBT-877, Single dose
DrugBank: BBT-877 (DB18668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of BBT-877, 5 dose levels, oral capsule
Trial: NCT03830125
Drug: BBT-877, Multiple doses
DrugBank: BBT-877 (DB18668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of BBT-877, 14 days, 8 dose levels, oral capsule
Trial: NCT02423902
Drug: Veledimex
RxNorm normalized name: Veledimex
DrugBank: Veledimex (DB12170)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 oral doses of veledimex
Trial: NCT03092453
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: administered 7-8 weeks after subject's last DC dose
Trial: NCT00152282
Drug: Asoprisnil/Premarin
DrugBank: Asoprisnil (DB06680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asoprisnil 10mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
Trial: NCT00152282
Drug: Asoprisnil/Premarin
DrugBank: Asoprisnil (DB06680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asoprisnil 25mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
Trial: NCT02812849
Drug: Cu-64 DOTATATE
RxNorm normalized name: copper Cu-64 dotatate
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03204019
Drug: Tegafur and Temozolomide
RxNorm normalized name: tegafur
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qd(d10-d14)
Trial: NCT03204019
Drug: Tegafur and Temozolomide combined with Thalidomide
RxNorm normalized name: tegafur
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qe(d10-d14) Thalidomide 100mg po qd(d1-d7) /Thalidomide 200mg po qd(d8-d14)/Thalidomide 300mg po qd(d15-d21)
Trial: NCT00002554
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02429271
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02429271
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01255878
Drug: Gabapentine
RxNorm normalized name: Gabapentine
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg(1 capsule)three times per day for two months
Trial: NCT01186588
Drug: Canagliflozin
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One 300-mg dose of canagliflozin on Day 1
Trial: NCT00073177
Drug: Roflumilast
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03128411
Drug: Bosutinib
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will receive bosutinib at a starting dose of 400 mg QD.
Trial: NCT03928353
Drug: PB2452 Infusion
RxNorm normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 minute - 24 hour infusion
Trial: NCT00419770
Drug: deferasirox
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20 mg/kg enterally per day
Trial: NCT00419770
Drug: Liposomal amphotericin B
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03928353
Drug: Placebo - Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 minute - 24 hour infusion
Trial: NCT03928353
Drug: Ticagrelor Oral Tablet - Pre-Treatment
RxNorm normalized name: ticagrelor Oral Tablet
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo
Trial: NCT03928353
Drug: Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
RxNorm normalized name: hydrocortisone
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo and Ticagrelor 180 mg 24 hours following PB2452 or Placebo
Trial: NCT03928353
Drug: Ticagrelor Oral Tablet - Pre-Treatment
RxNorm normalized name: ticagrelor Oral Tablet
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 180 mg BID for 5 doses prior to PB2452 or Placebo
Trial: NCT03928353
Drug: PB2452 Infusion
RxNorm normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 minute - 16 hour infusion
Trial: NCT03928353
Drug: Placebo - Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo - Sodium Chloride
Trial: NCT03501459
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01494506
Drug: MM-398
RxNorm normalized name: sodium phosphate, dibasic 398 MG
DrugBank: Sodium phosphate, dibasic (DB14502)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A: MM-398 120 mg/m2 IV Q3W~Arm C: MM-398 80mg/m2 IV Q2W
Trial: NCT04002297
Drug: zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered as two 80 mg capsules by mouth twice a day
Trial: NCT03456570
Drug: Dydrogesterone 10 mg
RxNorm normalized name: dydrogesterone 10 MG
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dydrogesterone 10 mg twice daily
Trial: NCT04002297
Drug: bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6
Trial: NCT04002297
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6
Trial: NCT01581970
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The initial dose of cetuximab 400 mg/m\^2 is administered over 120 minutes followed by weekly infusions of cetuximab 250 mg/m\^2 intravenously (IV) over 60 minutes.
Trial: NCT02339584
Drug: Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02339584
Drug: Brinzolamide 10 mg/mL eye drops, suspension
DrugBank: Brinzolamide (DB01194)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005948
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02339584
Drug: Brimonidine 2 mg/mL eye drops, solution
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03282643
Drug: Rivaroxaban 10 MG
RxNorm normalized name: rivaroxaban 10 MG
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban pill 10mg qd, day1 and day2 after femoral venepuncture
Trial: NCT03282643
Drug: Rivaroxaban 20 MG
RxNorm normalized name: rivaroxaban 20 MG
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban pill 10mg bid, day1 and day2 after femoral venepuncture
Trial: NCT00384566
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anit hypertensive medication
Trial: NCT00384566
Drug: Metoprolol
RxNorm normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti hypertensive medication
Trial: NCT00236457
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03101878
Drug: Ionis AGT-LRx
RxNorm normalized name: IONIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending single and multiple doses of Ionis AGT-LRx administered subcutaneously
Trial: NCT00414466
Drug: Intraspinal Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surgical implantation of a drug infusion system with intrathecal (spinal) delivery of active drug (1 of 3 possible dose levels) or placebo (saline) for 22 days followed by 7 days of infusion at half dose level. Subjects may then continue in open-label treatment with study drug. Dosage in open-label may be adjusted to meet subject needs.
Trial: NCT02680626
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given via transversus abdominis plane block
Trial: NCT02680626
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given via transversus abdominis plane block
Trial: NCT02999178
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04093167
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Per current Product Monograph/U.S. Drug Label and/or local guidelines.
Trial: NCT04590196
Drug: Longvida curcumin
DrugBank: Cumin (DB10864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: longvida curcumin verdure sciences formulation
Trial: NCT03381586
Drug: ALT-803
RxNorm normalized name: ALT-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN
DrugBank: Inbakicept (DB16479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to Group A will receive ALT-803 at a concentration of 1.0 mg/mL and subjects randomized to Group B will receive ALT-803 at a concentration of 2.0 mg/mL. Subjects will receive a single 10 µg/kg subQ dose of ALT-803 on Day 1 of study period 1. After a rest period, subjects will receive a single 20 µg/kg subQ dose of ALT-803 on Day 1 of study period 2.
Trial: NCT00077948
Drug: Enoximone
RxNorm normalized name: enoximone
DrugBank: Enoximone (DB04880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone administered orally
Trial: NCT00077948
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol succinate administered orally
Trial: NCT00077948
Drug: Placebo to match enoximone
RxNorm normalized name: enoximone
DrugBank: Enoximone (DB04880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match match enoximone administered orally
Trial: NCT00077948
Drug: Placebo to match metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo to match metoprolol succinate administered orally
Trial: NCT01931033
Drug: Intranasal Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01130519
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Commercially available. Administered by intravenous infusion.
Trial: NCT01130519
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available. Administered orally.